Analyst firms · Argus Research · MRNA

Argus Research MRNA price target and rating history

Moderna Inc. (MRNA) · Health Care

Argus Research rates Moderna Inc. (MRNA) Buy with a $180 price target, as of its latest action on Aug 28, 2026. It has published 3 rating actions on MRNA since June 2021, including 1 upgrade and 1 downgrade. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57. Argus Research's $180 is 216% above that.

Current rating
Buy
Price target
$180
Median target, all firms
$57
Actions on MRNA
3

Argus Research price target on MRNA

$230$205$18020222023202420252026
Argus Research price target on MRNA, each point a stated target, June 2021 to August 2026.

Every Argus Research rating on MRNA

How other firms rate MRNA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
William BlairMkt PerformOct 27, 2026
CitigroupSell$80Sep 30, 2026
Rothschild & Co RedburnSell$81Sep 3, 2026
Argus ResearchBuy$180Aug 28, 2026
Wolfe ResearchPeer PerformAug 25, 2026
BofA SecuritiesNeutralAug 19, 2026
BarclaysEqual Weight$25Jan 28, 2026
UBSNeutral$34Jan 7, 2026
JefferiesHold$30Dec 12, 2025

Questions about Argus Research and MRNA

What is Argus Research's price target for MRNA?
Argus Research's latest stated price target for Moderna Inc. (MRNA) is $180, from its action on Aug 28, 2026.
What is Argus Research's rating on MRNA?
Argus Research rates MRNA Buy, a bullish rating, as of Aug 28, 2026.
When did Argus Research last change its view on MRNA?
On Aug 28, 2026, Argus Research upgrades to Buy from Hold, price target $180.
How does Argus Research's MRNA target compare with other analysts?
Across 6 firms with a MRNA price target in the last 12 months, the median target is $57. Argus Research's $180 is 216% above that.

More MRNA rating histories

All Argus Research ratingsMRNA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.